Volume 58, Issue 1, Pages (January 2013)

Slides:

Advertisements

Similar presentations

EASL Clinical Practice Guidelines: Vascular diseases of the liver Journal of Hepatology Volume 64, Issue 1, Pages (January 2016) DOI: /j.jhep

Advertisements

Omega 3 – Omega 6: What is right for the liver? Ashraf Mohammad El-Badry, Rolf Graf, Pierre-Alain Clavien Journal of Hepatology Volume 47, Issue 5, Pages.

Global gene repression in hepatocellular carcinoma and fetal liver, and suppression of dudulin-2 mRNA as a possible marker for the cirrhosis-to-tumor transition.

From: Hepatitis B Virus Strains with Mutations in the Core Promoter in Patients with Fulminant Hepatitis Ann Intern Med. 1995;122(4): doi: /

Volume 63, Issue 1, Pages (July 2015)

Volume 46, Issue 3, Pages (March 2007)

Inflammasomes in liver diseases

Volume 61, Issue 4, Pages (October 2014)

Volume 50, Issue 4, Pages (April 2009)

Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: A systematic review Christian Thoma, Christopher P. Day, Michael.

Global trends and predictions in hepatocellular carcinoma mortality

Halis Simsek, Ali Shorbagi, Yasemin Balaban, Gonca Tatar

Matthew T. Kitson, Stuart K. Roberts Journal of Hepatology

Volume 42, Issue 1, Pages (January 2005)

NS5A inhibitors in the treatment of hepatitis C

Immigration and viral hepatitis

Determinants of hepatic effector CD8+ T cell dynamics

Individualized prediction of hepatocellular carcinoma occurrence in a large cohort of patients with cirrhosis Astrid Marot, Jean Henrion, Jean-François.

Hepatitis B and C virus-related carcinogenesis

Volume 66, Issue 1, Pages 1-4 (January 2017)

Liver transplantation for hepatitis B virus-related liver disease: Indications, prevention of recurrence and results Bruno Roche, Didier Samuel Journal.

Living donor liver transplantation: is the hype over?

Volume 69, Issue 2, Pages (August 2018)

Volume 44, Pages S19-S24 (January 2006)

Natural history and predictors of severity of chronic hepatitis C virus (HCV) and human immunodeficiency virus (HIV) co-infection Anaïs Vallet-Pichard,

The place of downstaging for hepatocellular carcinoma

How viral genetic variants and genotypes influence disease and treatment outcome of chronic hepatitis B. Time for an individualised approach? Neil Rajoriya,

Volume 61, Issue 2, Pages (August 2014)

Cheng-Yuan Peng, Rong-Nan Chien, Yun-Fan Liaw Journal of Hepatology

European Association for the Study of the Liver Journal of Hepatology

Volume 53, Issue 5, Pages (November 2010)

Volume 68, Issue 1, Pages (January 2018)

Hepatitis C core protein – The “core” of immune deception?

Marc van der Valk, Hans L. Zaaijer, Arnon P. Kater, Janke Schinkel

Volume 70, Issue 1, Pages (January 2019)

Statin use and the risk of hepatocellular carcinoma in patients at high risk: A nationwide nested case-control study Gyuri Kim, Suk-Yong Jang, Chung.

Why men are at higher risk for hepatocellular carcinoma?

Occult hepatitis B infection

Volume 62, Issue 3, Pages (March 2015)

Genomic risk of hepatitis C-related hepatocellular carcinoma

Autophagy in the liver Journal of Hepatology

Volume 59, Issue 3, Pages (September 2013)

Volume 49, Issue 4, Pages (October 2008)

Hepatitis B and C virus-related carcinogenesis

Volume 50, Issue 4, Pages (April 2009)

Antiviral therapy for chronic hepatitis B: Challenges in Hong Kong

Volume 61, Issue 1, Pages S79-S90 (November 2014)

Chetana Lim, Chady Salloum, Daniel Azoulay

Immigration and viral hepatitis

Kornelius Schulze, Jean-Charles Nault, Augusto Villanueva

Volume 60, Issue 5, Pages (May 2014)

Volume 63, Issue 1, Pages (July 2015)

Close monitoring of serum HBV DNA levels and liver enzymes levels is most useful in the management of patients with occult HBV infection Isabelle Chemin,

Volume 126, Issue 1, Pages (January 2004)

Volume 51, Issue 2, Pages (August 2009)

Hepatitis C infection: A multi-faceted systemic disease with clinical, patient reported and economic consequences Zobair M. Younossi, Aybike Birerdinc,

Volume 66, Issue 3, Pages (March 2017)

Volume 49, Issue 1, Pages (July 2008)

Integrating sorafenib into an algorithm for the management of post-transplant hepatocellular carcinoma recurrence Christian Toso, Gilles Mentha, Pietro.

Liver transplantation in children

Pathogenesis of cholestatic hepatitis C

Genetic alterations in advanced HBV-related HCC with portal vein tumor thrombosis: Insights from next generation DNA sequencing Roongruedee Chaiteerakij,

Chimeric mouse model of hepatitis B virus infection

Volume 50, Issue 1, Pages 4-6 (January 2009)

Genetics of hepatocellular carcinoma: The next generation

Volume 70, Issue 5, Pages (May 2019)

Volume 56, Issue 3, Pages (March 2012)

Outcomes in liver transplantation: Does sex matter?

Reversion of disease manifestations after HCV eradication

Volume 53, Issue 4, Pages (October 2010)

Presentation transcript:

Volume 58, Issue 1, Pages 190-193 (January 2013) Hepatitis B virus DNA integration in tumour tissue of a non-cirrhotic HFE- haemochromatosis patient with hepatocellular carcinoma Teresa Pollicino, Alberto Vegetti, Carlo Saitta, Francesca Ferrara, Elena Corradini, Giuseppina Raffa, Antonello Pietrangelo, Giovanni Raimondo Journal of Hepatology Volume 58, Issue 1, Pages 190-193 (January 2013) DOI: 10.1016/j.jhep.2012.09.005 Copyright © 2012 European Association for the Study of the Liver Terms and Conditions

Fig. 1 Schematic representation of HBV DNA integration site. Shaded box, HBV sequence. The region corresponding to the basic core promoter (BCP) and enhancer II is indicated within the viral sequences by the filled black box. Numbering of nucleotides is according to HBV ayw subtype. Open box, PARD6G coding sequence. Bold arrowheads, orientation of the ORF. The distance between the HBV integration site and the gene ATG is indicated (3.7kb). Journal of Hepatology 2013 58, 190-193DOI: (10.1016/j.jhep.2012.09.005) Copyright © 2012 European Association for the Study of the Liver Terms and Conditions